Clinical Trial Update: A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of famitinib malate in HER2-negative metastatic breast cancer has completed; this update reports the trial status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Famitinib malate (famitinib malate)

Snippet

Sponsor: Fudan University | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED